Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 147084-10-4
2. Lastacaft
3. R89674
4. R-89674
5. R 89674
6. 7z8o94ecsx
7. Chebi:71023
8. 11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde
9. Lastacaft (tn)
10. 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5h-imidazo[2,1-b][3]benzazepine-3-carbaldehyde
11. 2-(1-methylpiperidin-4-ylidene)-4,7-diazatricyclo[8.4.0.0(3,7)]tetradeca- 1(14),3,5,10,12-pentaene-6-carbaldehyde
12. Alcaftadine [usan:inn]
13. Unii-7z8o94ecsx
14. Alcaftadina
15. Alcaftadinum
16. 5h-imidazo(2,1-b)(3)benzazepine-3-carboxaldehyde, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-
17. 5h-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde, 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-
18. Alcaftadine [inn]
19. Alcaftadine [jan]
20. Alcaftadine [usan]
21. Alcaftadine [vandf]
22. Alcaftadine [mart.]
23. Alcaftadine [who-dd]
24. Alcaftadine (jan/usan/inn)
25. Gtpl7587
26. Schembl1602418
27. Chembl1201747
28. Alcaftadine, >=98% (hplc)
29. (unlabelled)alcaftadine-13c-d3
30. Alcaftadine [orange Book]
31. Dtxsid80598455
32. Hms3885b12
33. Bcp04261
34. Mfcd09954106
35. S4625
36. Zinc11726211
37. Akos025402002
38. Am84429
39. Bcp9000269
40. Ccg-267551
41. Db06766
42. Ncgc00390732-04
43. 5h-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde,6,11-dihydro-11-(1-methyl-4-piperidinylidene)-
44. Ac-28019
45. As-56303
46. Hy-17039
47. Bcp0726000082
48. Db-063693
49. Ft-0661472
50. A16393
51. D06552
52. Q4712900
53. 11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,3-b][3]benzazepine-3-carbaldehyde
54. 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5h-benzo[d]imidazo[1,2-a]azepine-3-carbaldehyde
55. 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5h-imidazolo(2,1-b)(3)benzazepine-3-carbaldehyde
56. 2-(1-methylpiperidin-4-ylidene)-4,7-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(14),3,5,10,12-pentaene-6-carbaldehyde
57. 4-(1-methyl-piperidin-4-ylidene)-9,10-dihydro-4h-3,10a-diaza-benzo(f)azulene-1-carbaldehyde
58. 5h-imidazo(2,1-b)(3)benzazepine-3-carboxaldehyde, 6,11-dihydro-11-(1-methyl-4- Piperidinylidene)-
Molecular Weight | 307.4 g/mol |
---|---|
Molecular Formula | C19H21N3O |
XLogP3 | 1.7 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 1 |
Exact Mass | 307.168462302 g/mol |
Monoisotopic Mass | 307.168462302 g/mol |
Topological Polar Surface Area | 38.1 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 479 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Lastacaft |
PubMed Health | Alcaftadine (Into the eye) |
Drug Classes | Ophthalmologic Agent |
Drug Label | LASTACAFT is a sterile, topically administered H1 receptor antagonist containing alcaftadine for ophthalmic use. Alcaftadine is a white to yellow powder with an empirical formula of C19H21N3O and a molecular weight of 307.39. Contains: Active: alca... |
Active Ingredient | Alcaftadine |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 0.25% |
Market Status | Prescription |
Company | Allergan |
2 of 2 | |
---|---|
Drug Name | Lastacaft |
PubMed Health | Alcaftadine (Into the eye) |
Drug Classes | Ophthalmologic Agent |
Drug Label | LASTACAFT is a sterile, topically administered H1 receptor antagonist containing alcaftadine for ophthalmic use. Alcaftadine is a white to yellow powder with an empirical formula of C19H21N3O and a molecular weight of 307.39. Contains: Active: alca... |
Active Ingredient | Alcaftadine |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 0.25% |
Market Status | Prescription |
Company | Allergan |
For the prevention of itching associated with allergic conjunctivitis.
FDA Label
Following bilateral topical ocular administration of alcaftadine ophthalmic solution, 0.25%, the mean plasma Cmax of alcaftadine was approximately 60 pg/mL and the median Tmax occurred at 15 minutes. Plasma concentrations of alcaftadine were below the lower limit of quantification (10 pg/mL) by 3 hours after dosing. The mean Cmax of the active carboxylic acid metabolite was approximately 3 ng/mL and occurred at 1 hour after dosing. Plasma concentrations of the carboxylic acid metabolite were below the lower limit of quantification (100 pg/mL) by 12 hours after dosing.
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
S - Sensory organs
S01 - Ophthalmologicals
S01G - Decongestants and antiallergics
S01GX - Other antiallergics
S01GX11 - Alcaftadine
Route of Elimination
Based on data following oral administration of alcaftadine, the carboxylic acid metabolite is primarily eliminated unchanged in the urine.
The metabolism of alcaftadine is mediated by non-CYP450 cytosolic enzymes to the active carboxylic acid metabolite.
The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration.
Alcaftadine is a H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-01-05
Pay. Date : 2014-11-24
DMF Number : 28277
Submission : 2014-05-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20066
Submission : 2006-12-21
Status : Active
Type : II
NDC Package Code : 12502-5263
Start Marketing Date : 2010-01-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : AbbVie Korea Inc.
Registration Date : 2012-04-20
Registration Number : 5242-3-ND
Manufacturer Name : Cilag AG
Manufacturer Address : Hochstrasse 201, 8200 Schaffhausen
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32382
Submission : 2018-01-07
Status : Active
Type : II
NDC Package Code : 42973-204
Start Marketing Date : 2017-12-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-04-15
Pay. Date : 2016-03-24
DMF Number : 28932
Submission : 2015-02-04
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm :
NDC Package Code : 14501-0020
Start Marketing Date : 2015-02-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-04-11
Pay. Date : 2014-02-24
DMF Number : 27982
Submission : 2014-02-18
Status : Active
Type : II
NDC Package Code : 65089-0063
Start Marketing Date : 2023-03-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27559
Submission : 2013-12-21
Status : Inactive
Type : II
Date of Issue : 2022-01-04
Valid Till : 2022-07-14
Written Confirmation Number : WC-0021A4
Address of the Firm :
NDC Package Code : 14501-0020
Start Marketing Date : 2015-02-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Alcaftadine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alcaftadine, including repackagers and relabelers. The FDA regulates Alcaftadine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alcaftadine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Alcaftadine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Alcaftadine supplier is an individual or a company that provides Alcaftadine active pharmaceutical ingredient (API) or Alcaftadine finished formulations upon request. The Alcaftadine suppliers may include Alcaftadine API manufacturers, exporters, distributors and traders.
click here to find a list of Alcaftadine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Alcaftadine DMF (Drug Master File) is a document detailing the whole manufacturing process of Alcaftadine active pharmaceutical ingredient (API) in detail. Different forms of Alcaftadine DMFs exist exist since differing nations have different regulations, such as Alcaftadine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Alcaftadine DMF submitted to regulatory agencies in the US is known as a USDMF. Alcaftadine USDMF includes data on Alcaftadine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Alcaftadine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Alcaftadine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Alcaftadine Drug Master File in Korea (Alcaftadine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Alcaftadine. The MFDS reviews the Alcaftadine KDMF as part of the drug registration process and uses the information provided in the Alcaftadine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Alcaftadine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Alcaftadine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Alcaftadine suppliers with KDMF on PharmaCompass.
A Alcaftadine written confirmation (Alcaftadine WC) is an official document issued by a regulatory agency to a Alcaftadine manufacturer, verifying that the manufacturing facility of a Alcaftadine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Alcaftadine APIs or Alcaftadine finished pharmaceutical products to another nation, regulatory agencies frequently require a Alcaftadine WC (written confirmation) as part of the regulatory process.
click here to find a list of Alcaftadine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Alcaftadine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Alcaftadine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Alcaftadine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Alcaftadine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Alcaftadine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Alcaftadine suppliers with NDC on PharmaCompass.
Alcaftadine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alcaftadine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alcaftadine GMP manufacturer or Alcaftadine GMP API supplier for your needs.
A Alcaftadine CoA (Certificate of Analysis) is a formal document that attests to Alcaftadine's compliance with Alcaftadine specifications and serves as a tool for batch-level quality control.
Alcaftadine CoA mostly includes findings from lab analyses of a specific batch. For each Alcaftadine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alcaftadine may be tested according to a variety of international standards, such as European Pharmacopoeia (Alcaftadine EP), Alcaftadine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alcaftadine USP).
LOOKING FOR A SUPPLIER?